Veradermics completes enrollment in both Phase 3 male hair loss trials
The milestone means more than 1,000 men are now enrolled across both Phase 3 programs
The milestone means more than 1,000 men are now enrolled across both Phase 3 programs
Anand Chemiceutics serves over 1,500 laboratories, hospitals, and government institutions
This achievement validates global demand and catapults Wanbury into high-growth acceleration
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
Subscribe To Our Newsletter & Stay Updated